Switch to: References

Add citations

You must login to add citations.
  1. Ethical Dimensions of Disparities in Depression Research and Treatment in the Pharmacogenomic Era.Lisa S. Parker & Valerie B. Satkoske - 2012 - Journal of Law, Medicine and Ethics 40 (4):886-903.
    Disparities in access to, and utilization of, treatment for depression among African-American and Caucasian elderly adults have been well-documented. Less fully explored are the multidimensional factors responsible for these disparities. The intersection of cultural constructs, socioeconomic factors, multiple levels of racism, and stigma attending both mental health issues and older age may help to explain disparities in the treatment of the depressed elderly. Personalized medicine with its promise of developing interventions tailored to an individual's health needs and genetically related response (...)
    Direct download (6 more)  
     
    Export citation  
     
    Bookmark  
  • Ethical Dimensions of Disparities in Depression Research and Treatment in the Pharmacogenomic Era.Lisa S. Parker & Valerie B. Satkoske - 2012 - Journal of Law, Medicine and Ethics 40 (4):886-903.
    Personalized medicine with its promise of developing interventions tailored to an individual's health need and genetically related response to treatment might seem a promising antidote to the documented underutilization of standard depression treatments by African Americans. In addition, understanding depression not merely in biochemical terms but also in genetic terms might seem to counter cultural beliefs and stigma that attach to depression when conceived as a mood or behavioral problem under an individual's control. After all, if there is one thing (...)
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark  
  • Grassroots Marketing in a Global Era: More Lessons From BiDil.Britt M. Rusert & Charmaine D. M. Royal - 2011 - Journal of Law, Medicine and Ethics 39 (1):79-90.
    BiDil, a heart failure drug for African Americans, emerged five years ago as the first FDA approved drug targeted at a specific racial group. While critical scholarship and the popular media have meticulously detailed the history of BiDil from its inauspicious beginnings as a generic combination drug for the general population to its dramatic resuscitation as a racial medicine, the enthusiastic support shown by some African American interest groups has been too little understood, as has their argument that BiDil was (...)
    Direct download (6 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  • Grassroots Marketing in a Global Era: More Lessons From BiDil.Britt M. Rusert & Charmaine D. M. Royal - 2011 - Journal of Law, Medicine and Ethics 39 (1):79-90.
    Since the first phase of the formal effort to sequence the human genome, geneticists, social scientists and other scholars of race and ethnicity have warned that new genetic technologies and knowledge could have negative social effects, from biologizing racial and ethnic categories to the emergence of dangerous forms of genetic discrimination. Early on in the Human Genome Project, population geneticists like Luigi Luca Cavalli-Sforza enthusiastically advocated for the collection of DNA samples from global indigenous populations in order to track the (...)
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark